
    
      The trial is an open label extension study. Eligible patients from the RPC01-3101 and
      RPC01-202 trials will have the option to enroll in this trial to receive study medication
      until the end of 2021 or until marketing approval of RPC1063 for UC is obtained in their
      country, or until the Sponsor discontinues the development program, whichever comes first.
    
  